LifeTime: improving European healthcare through cell-based interceptive medicine

LifeTime initiative is developing a fundamentally new approach to understanding the constant changes within cells and their relationships, thus creating the foundation for the precision medicines of the future. Hundreds of researchers, clinicians, industry leaders and policy makers from all around Europe are united by a vision of how to revolutionize healthcare. In a perspective in Nature and the LifeTime Strategic Research Agenda they now present a roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual’s lifetime.

The LifeTime initiative, co-coordinated by two EU-LIFE members, the Max Delbrück Center of Molecular Medicine in the Helmholtz Association (MDC) in Berlin and the Institut Curie in Paris, has developed a strategy to advance personalized treatment for five major disease classes: cancer, neurological, infectious, chronic inflammatory and cardiovascular diseases. The aim is a new age of personalized, cell-based interceptive medicine for Europe with the potential of improved health outcomes and more cost-effective treatment, resulting in profoundly changing a person’s healthcare experience.
EU-LIFE is an associated partner of this breakthrough initiative which includes several EU-LIFE members.